Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

FDA Seeks Power for Eyedrops Recalls Amid Foreign Inspections Woes

U.S. health officials grapple with inadequate inspection of overseas eyedrop factories, leading to recalls of potentially dangerous products.

Top News

Safer eyedrops will require new FDA powers and resources, experts say

Repeated recalls of eyedrops are drawing new attention to the limited powers U.S. regulators have to oversee medical products made overseas

The Independent UK

Pfizer Crashes 7% After Issuing A Disappointing Outlook As Seagen Takeover Looms

Pfizer stock careened lower Wednesday after the company issued disappointing 2024 guidance ahead of its acquisition of Seagen.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer tumbles after muted 2024 revenue forecast, Seagen profits hit

Pfizer, which saw revenue top $100 billion in 2022, has shed more than $143 billion in market value this year.

The Street

Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine

Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology. But gene editing therapies aren’t without risk, and questions remain about the safety and cost effectiveness of these experimental treatments.

Investors Business Daily

AstraZeneca buys US vaccine company in $1.1bn deal

Britain’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business

The Guardian - UK

Citius Pharmaceuticals (CTXR) Earnings Watch: Pharma Stock Signals for Investors

Citius Pharmaceuticals (CTXR) has been making significant progress in its pipeline, garnering investors' attention. However, considering that CTXR is an unprofitable and pre-revenue business, is it worth investing now as the company prepares to report quarterly results? Keep reading.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Pharma Powerhouses to Boost Your Year-End Investments

Backed by an ever-growing need for chronic disease treatments, rapid investments in research and development, and widespread integration of technology, the pharmaceutical sector is anticipated to flourish. Thus, as we approach the end of 2023, three solid pharma stocks, GoodRx Holdings (GDRX), CytomX Therapeutics (CTMX), and Neurocrine Biosciences (NBIX), could…

StockNews.com

3 Pharma Stocks Flashing 'Buy' Signals in December

The pharmaceutical industry is well-positioned for robust growth, driven by growing healthcare expenditure globally and the rapid adoption of digital technologies. Given the industry’s tailwinds, fundamentally strong pharma stocks, Collegium Pharmaceutical (COLL), Eton Pharmaceuticals (ETON), and GSK plc (GSK) could be ideal buys this month. Continue Reading….

StockNews.com

DeSantis raises eyebrows by telling GOP debate his favourite president is Calvin Coolidge

‘He’s one of the few presidents that got almost everything right. He understood the proper role of the federal government under the Constitution,’ DeSantis says

The Independent UK

DCA busts spurious anti-cancer drug racket, ₹4.35 crore stock seized

The Hindu

The Guardian view on cystic fibrosis treatments: a rollercoaster ride for the sick

Editorial: Patients are facing shorter lives as drug companies are demanding prices that health services here and in other countries cannot pay

The Guardian - UK

CVS Health higher on dividend boost and solid 2024 revenue forecast

CVS Health, facing the potential for deeper industry consolidation, lifted its 2024 sales forecast and boosted its quarterly dividend.

The Street

Divided US High Court Hears Challenge To $6bn Purdue Opioid Settlement

The US Supreme Court appeared divided on Monday as it heard a challenge to Purdue Pharma's $6 billion opioids settlement immunizing the Sackler family that controlled the drugmaker from future litigation.

International Business Times

Get all your
news in one place.

100’s of premium titles.
One news app.

Caixin Global

WuXi Biologics Plunges on Concerns over Cooling Biotech Market

Leading Chinese drug company estimates $100 million net loss in 2023 as biotech funding slows and Covid related income falls

The Independent UK

The Sackler family wants protection from opioid lawsuits. Will the Supreme Court grant it?

A bankruptcy case before the Supreme Court could grant the Sackler family immunity from opioid-related civil cases Ariana Baio reports

AAP

Opioid users to get greater access to overdose drug

Access to an overdose reversal drug has been expanded in Victoria, almost 18 months after the federal government allowed it.

AAP

Blackmores unit allegedly fired health whistleblower

An employee of a Blackmores subsidiary has claimed the firm terminated him instead of dealing with health concerns raised about two of its vitamin products.

Get all your
news in one place.

100’s of premium titles.
One news app.

International Business Times

US High Court To Hear Challenge To $6bn Purdue Opioid Settlement

The US Supreme Court is to hear a challenge on Monday to Purdue Pharma's $6 billion opioids settlement immunizing the family that controlled the drugmaker from future litigation.

StockNews.com

3 Pharma Stocks Navigating Future Investments - Buy Now

The pharmaceutical industry is evolving with changing consumer behavior, rapid adoption of digital solutions, and global expansion. Hence, fundamentally strong pharma stocks Zoetis (ZTS), Wave Life Sciences (WVE), and Johnson & Johnson (JNJ) might be solid investments now. Read more….

StockNews.com

Are These 3 Pharma Stocks a Buy or Hold Opportunity for December?

The pharmaceutical industry looks well-positioned for long-term growth. So, let us analyze pharma stocks Procaps Group (PROC), Voyager Therapeutics (VYGR) and Organon & Co. (OGN) to identify whether they are a Buy or Hold. Read on.

Investors Business Daily

AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal

AbbVie agreed to buy ImmunoGen for $10.1 billion in cash, offering a rich premium for the maker of ovarian cancer treatment drug Elahere.

AAP

Carr calls for courage ahead of next drug summit

Courage remains vital in drug policy, former NSW premier Bob Carr says as he and fellow players in a landmark drug summit press for more change.

StockNews.com

3 Pharma Stocks on the Rise - It's Time to Buy Now

The pharma industry’s long-term solid outlook is driven by steady demand for drugs due to the rising frequency of chronic conditions and growing geriatric population coupled with rapid technological innovations. Hence, quality pharma stocks, CytomX Therapeutics (CTMX), Eton Pharmaceuticals (ETON), and GSK (GSK), might be solid investments now for potential…

Investors Business Daily

Argenx Stock Crashes On An Unexpected Failure For Its Biggest Drug

Argenx stock plummeted Tuesday after the company's drug unexpectedly failed to help patients with a rare blood disorder.

1 … 19 20 21 22

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Justice Department

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.